CONFLICT OF INTEREST STATEMENT
JENSEN
K.L.-S.’s salary was partially funded by Kappa Bioscience AS, the Danish Society of Nephrology and the Karen Elise Jensen Foundation during the RenaKvit trial. M.F.H. has received a research grant from Orkla Care AS. B.L. has received research grants from Amgen and honoraria for academic services from Amgen, UCB, Gilead, Astellas, AstraZeneca and Gedeon-Richter, unrelated to the RenaKvit trial. The remaining authors have nothing to declare.